JP2019196365A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019196365A5 JP2019196365A5 JP2019117073A JP2019117073A JP2019196365A5 JP 2019196365 A5 JP2019196365 A5 JP 2019196365A5 JP 2019117073 A JP2019117073 A JP 2019117073A JP 2019117073 A JP2019117073 A JP 2019117073A JP 2019196365 A5 JP2019196365 A5 JP 2019196365A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- bispecific fusion
- tissue
- protein according
- bispecific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020001507 fusion proteins Proteins 0.000 claims 15
- 102000037865 fusion proteins Human genes 0.000 claims 15
- 210000001519 tissue Anatomy 0.000 claims 4
- 239000012634 fragment Substances 0.000 claims 3
- 210000005084 renal tissue Anatomy 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 claims 1
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102100023635 Alpha-fetoprotein Human genes 0.000 claims 1
- 108090000672 Annexin A5 Proteins 0.000 claims 1
- 102000004121 Annexin A5 Human genes 0.000 claims 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 claims 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 claims 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 claims 1
- 102000007584 Prealbumin Human genes 0.000 claims 1
- 108010071690 Prealbumin Proteins 0.000 claims 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims 1
- 102000050760 Vitamin D-binding protein Human genes 0.000 claims 1
- 101710179590 Vitamin D-binding protein Proteins 0.000 claims 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000000601 blood cell Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 230000006041 cell recruitment Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 210000005003 heart tissue Anatomy 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 210000001503 joint Anatomy 0.000 claims 1
- 210000005228 liver tissue Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 210000004923 pancreatic tissue Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 230000001629 suppression Effects 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34704010P | 2010-05-21 | 2010-05-21 | |
| US61/347,040 | 2010-05-21 | ||
| US13/112,907 US8691771B2 (en) | 2010-05-21 | 2011-05-20 | Bi-specific fusion proteins for tissue repair |
| US13/112,907 | 2011-05-20 | ||
| US13/068,808 US9238080B2 (en) | 2010-05-21 | 2011-05-20 | Bi-specific fusion proteins |
| US13/068,808 | 2011-05-20 | ||
| JP2017132859A JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132859A Division JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019196365A JP2019196365A (ja) | 2019-11-14 |
| JP2019196365A5 true JP2019196365A5 (enExample) | 2020-02-13 |
| JP6965311B2 JP6965311B2 (ja) | 2021-11-10 |
Family
ID=44972647
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511403A Active JP6200806B2 (ja) | 2010-05-21 | 2011-05-20 | 二重特異的融合タンパク質 |
| JP2016130526A Active JP6174763B2 (ja) | 2010-05-21 | 2016-06-30 | 二重特異的融合タンパク質 |
| JP2017132859A Active JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
| JP2019117073A Active JP6965311B2 (ja) | 2010-05-21 | 2019-06-25 | 二重特異的融合タンパク質 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013511403A Active JP6200806B2 (ja) | 2010-05-21 | 2011-05-20 | 二重特異的融合タンパク質 |
| JP2016130526A Active JP6174763B2 (ja) | 2010-05-21 | 2016-06-30 | 二重特異的融合タンパク質 |
| JP2017132859A Active JP6822911B2 (ja) | 2010-05-21 | 2017-07-06 | 二重特異的融合タンパク質 |
Country Status (9)
| Country | Link |
|---|---|
| US (11) | US8691771B2 (enExample) |
| EP (1) | EP2571992B1 (enExample) |
| JP (4) | JP6200806B2 (enExample) |
| CN (1) | CN103124788B (enExample) |
| AU (1) | AU2011255238B2 (enExample) |
| BR (1) | BR112012029611A2 (enExample) |
| CA (1) | CA2800173C (enExample) |
| ES (1) | ES2674567T3 (enExample) |
| WO (1) | WO2011146902A1 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5677972B2 (ja) * | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| CN102317315A (zh) | 2009-02-11 | 2012-01-11 | 诺维信生物制药丹麦公司 | 白蛋白变体和缀合物 |
| WO2011051489A2 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| WO2011103076A1 (en) * | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
| US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
| EP2571992B1 (en) | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
| US20140121163A1 (en) * | 2011-04-28 | 2014-05-01 | The Feinstein Institute for Medical Research a corporation | Mfg-e8 and uses thereof |
| CN110272484A (zh) | 2011-05-05 | 2019-09-24 | 阿尔布梅迪克斯医疗有限公司 | 白蛋白变体 |
| TWI679212B (zh) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | 針對ｂｃｍａ之e3以及ｃｄ３的結合分子 |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| ES2664328T3 (es) | 2012-03-16 | 2018-04-19 | Albumedix A/S | Variantes de albúmina |
| US9289507B2 (en) | 2012-05-17 | 2016-03-22 | Extend Biosciences, Inc. | Carriers for improved drug delivery |
| US9790264B2 (en) | 2012-06-25 | 2017-10-17 | The Brigham And Women's Hospital, Inc. | Compounds and methods for modulating pharmacokinetics |
| DK2864360T3 (en) | 2012-06-25 | 2017-12-18 | Brigham & Womens Hospital Inc | TARGETED THERAPY |
| US9345766B2 (en) | 2012-08-30 | 2016-05-24 | Merrimack Pharmaceuticals, Inc. | Combination therapies comprising anti-ERBB3 agents |
| EP2917233A1 (en) | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
| CN105518143B (zh) * | 2013-03-15 | 2020-02-21 | 北京凯得尔森生物技术有限公司 | 融合蛋白分子和它的使用方法 |
| JP2017518965A (ja) | 2014-05-02 | 2017-07-13 | モメンタ ファーマシューティカルズ インコーポレイテッ | エンジニアリングされたＦｃ構築物に関連する組成物および方法 |
| US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
| US20170204149A1 (en) * | 2014-06-23 | 2017-07-20 | Novartis Ag | Hsa-gdf-15 fusion polypeptide and use thereof |
| CN105273087A (zh) * | 2014-07-14 | 2016-01-27 | 复旦大学 | NGF-Fc融合蛋白及其制备方法 |
| WO2016065042A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| EP3283068A1 (en) | 2015-04-17 | 2018-02-21 | Merrimack Pharmaceuticals, Inc. | Combination treatments with seribantumab |
| CN104946656B (zh) * | 2015-06-08 | 2018-08-17 | 吉林省农业科学院 | 一种人源碱性成纤维细胞生长因子、烟草叶绿体表达载体及生产方法 |
| TWI744242B (zh) | 2015-07-31 | 2021-11-01 | 德商安美基研究（慕尼黑）公司 | Egfrviii及cd3抗體構築體 |
| TWI796283B (zh) | 2015-07-31 | 2023-03-21 | 德商安美基研究（慕尼黑）公司 | Ｍｓｌｎ及ｃｄ３抗體構築體 |
| TWI829617B (zh) | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| EA039859B1 (ru) * | 2015-07-31 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Биспецифические конструкты антител, связывающие egfrviii и cd3 |
| JP7007261B2 (ja) | 2015-08-20 | 2022-01-24 | アルブミディクス リミティド | アルブミン変異体及びコンジュゲート |
| GB2542391A (en) * | 2015-09-17 | 2017-03-22 | Annexin Pharmaceuticals Ab | Process of manufacture |
| ES2863278T3 (es) * | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Proteínas terapéuticas biespecíficas para la reparación de tejidos |
| EP3395366B1 (en) * | 2015-12-21 | 2023-11-22 | Hefei Lifeon Pharmaceutical Co., Ltd. | Drug design method, obtained drug and application thereof |
| JP6904959B2 (ja) * | 2016-01-04 | 2021-07-21 | クール ファーマシューティカルズ ディベロップメント カンパニー インコーポレイテッド | 結合エピトープを含有する融合タンパク質を封入する粒子 |
| PL3411402T3 (pl) | 2016-02-03 | 2022-02-28 | Amgen Research (Munich) Gmbh | Konstrukty bispecyficznych przeciwciał angażujących komórki T BCMA i CD3 |
| WO2017134158A1 (en) | 2016-02-03 | 2017-08-10 | Amgen Research (Munich) Gmbh | Psma and cd3 bispecific t cell engaging antibody constructs |
| EP3423572B1 (en) | 2016-03-02 | 2023-11-29 | Momenta Pharmaceuticals, Inc. | Methods related to engineered fc constructs |
| KR20180119570A (ko) | 2016-03-15 | 2018-11-02 | 메리맥 파마슈티컬즈, 인크. | 항-ErbB3 항체를 포함하는 병용 요법을 이용한 ER+, HER2-, HRG+ 유방암의 치료 |
| WO2017205436A1 (en) * | 2016-05-23 | 2017-11-30 | Momenta Pharmaceuticals, Inc. | Compositions and methods related to engineered fc constructs |
| US11220531B2 (en) | 2017-01-06 | 2022-01-11 | Janssen Biotech, Inc. | Engineered Fc constructs |
| EP3649147A4 (en) | 2017-07-03 | 2021-04-14 | Torque Therapeutics, Inc. | POLYNUCLEOTIDES CODING IMMUNOSTIMULANT FUSION MOLECULES AND THEIR USES |
| JP7221545B2 (ja) * | 2017-07-24 | 2023-02-14 | ラトガース，ザ ステート ユニバーシティ オブ ニュー ジャージー | ホスファチジルセリン標的化融合分子およびそれらの使用方法 |
| CN113214410A (zh) * | 2017-11-04 | 2021-08-06 | 海南大学 | 一种表达促皮质素与胰岛素样生长因子1融合蛋白的重组质粒、重组菌的构建方法 |
| US11464803B2 (en) * | 2017-11-14 | 2022-10-11 | Arcellx, Inc. | D-domain containing polypeptides and uses thereof |
| GB201919019D0 (en) * | 2019-12-20 | 2020-02-05 | Autolus Ltd | Antigen-binding domain |
| EP4103609A1 (en) * | 2020-02-13 | 2022-12-21 | UCB Biopharma SRL | Bispecific antibodies against cd9 and cd7 |
| CN116917482A (zh) | 2020-07-30 | 2023-10-20 | 银溪制药股份有限公司 | 嵌合蛋白和治疗中枢神经系统疾病的方法 |
| CN115286713B (zh) * | 2020-10-27 | 2024-07-23 | 温州医科大学 | 一种以结缔组织生长因子为靶点的全人源拮抗抗体及其应用 |
| JP2023550895A (ja) * | 2020-10-30 | 2023-12-06 | セレメディー カンパニー，リミテッド | 抗体様タンパク質およびその用途 |
| US11946055B2 (en) * | 2020-12-10 | 2024-04-02 | The Regents Of The University Of California | Protein engineering via error-prone orthogonal replication and yeast surface display |
| JP2024519578A (ja) * | 2021-05-03 | 2024-05-17 | セレメディー カンパニー，リミテッド | 新規タンパク質 |
| CN117659178B (zh) * | 2022-08-23 | 2024-09-24 | 东莞市朋志生物科技有限公司 | 抗甲型流感病毒抗体或其功能性片段、检测甲型流感病毒的试剂和试剂盒 |
| US12233115B2 (en) | 2022-09-30 | 2025-02-25 | Extend Biosciences, Inc. | Long-acting parathyroid hormone |
| CN118420712A (zh) * | 2023-02-01 | 2024-08-02 | 上海健信生物医药科技有限公司 | 一种三特异性抗体技术平台及其应用 |
| CN116983407B (zh) * | 2023-08-03 | 2025-10-28 | 艾可泰科(浙江)控股有限公司 | 一种治疗膝关节炎的新一代干细胞治疗剂及其制备工艺 |
| CN117736344B (zh) * | 2024-01-30 | 2024-06-21 | 南通大学 | 具有自组装性能的重复结构单元重组蛋白ⅡAⅡB-ⅡAⅡBrQTY及应用 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8819826D0 (en) | 1988-08-20 | 1988-09-21 | Kabivitrum Ab | Glycosylated igf-1 |
| US6541610B1 (en) * | 1989-09-05 | 2003-04-01 | Immunex Corporation | Fusion proteins comprising tumor necrosis factor receptor |
| US5679771A (en) | 1990-02-13 | 1997-10-21 | Gropep Pty. Ltd. | Method for treating intestinal diseases |
| US6566098B1 (en) | 1990-09-14 | 2003-05-20 | The United States Of America As Represented By The Department Of Health And Human Services | DNA encoding truncated hepatocyte growth factor variants |
| EP0574395B1 (en) | 1990-11-09 | 2002-06-12 | GILLIES, Stephen D. | Cytokine immunoconjugates |
| US5632986A (en) | 1991-05-09 | 1997-05-27 | The University Of Washington | Phospholipid-targeted thrombolytic agents |
| AU7042994A (en) * | 1993-05-21 | 1994-12-20 | Amgen, Inc. | Recombinant (neu) differentiation factors |
| CA2190752A1 (en) | 1994-05-24 | 1995-11-30 | George N. Cox | Modified insulin-like growth factors |
| US5780052A (en) | 1995-04-24 | 1998-07-14 | Northeastern University | Compositions and methods useful for inhibiting cell death and for delivering an agent into a cell |
| CA2224859A1 (en) | 1996-04-17 | 1997-10-23 | Amitabh Gaur | Ligand inhibitors of insulin-like growth factor binding proteins and methods of use therefor |
| US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
| IL140700A0 (en) * | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using therapeutic conjugates that bind to aminophospholipids |
| US6387663B1 (en) * | 1998-07-31 | 2002-05-14 | University Of Southern California | Targeting pharmaceutical agents to injured tissues |
| AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
| IL143834A0 (en) | 1999-01-06 | 2002-04-21 | Genentech Inc | Insulin-like growth factor (igf) i mutant variants |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP1223953B1 (en) | 1999-07-21 | 2006-02-01 | University of Southern California | Matrix-targeted fusion polypeptides for tissue regeneration and wound healing |
| GB2360771A (en) * | 2000-03-28 | 2001-10-03 | Antisoma Res Ltd | Compounds for targeting |
| CA2419561A1 (en) | 2000-08-29 | 2002-03-07 | Colorado State University Research Foundation | Method for treating the central nervous system by administration of igf structural analogs |
| SG138469A1 (en) | 2001-01-05 | 2008-01-28 | Pfizer | Antibodies to insulin-like growth factor i receptor |
| US7635680B2 (en) * | 2001-02-21 | 2009-12-22 | Alavita Pharmaceuticals, Inc. | Attenuation of reperfusion injury |
| IL158623A0 (en) | 2001-04-30 | 2004-05-12 | Symbiontics Inc | Subcellular targeting of therapeutic proteins |
| US7049286B2 (en) * | 2001-08-30 | 2006-05-23 | Diatos, S.A. | Insulin conjugates and methods of use thereof |
| AU2008200706B2 (en) | 2001-10-16 | 2010-05-27 | Biomarin Pharmaceutical Inc. | Methods and compositions for targeting underglycosylated proteins across the blood brain barrier |
| US20030072761A1 (en) | 2001-10-16 | 2003-04-17 | Lebowitz Jonathan | Methods and compositions for targeting proteins across the blood brain barrier |
| WO2005077042A2 (en) * | 2004-02-09 | 2005-08-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2003241313A1 (en) | 2002-04-23 | 2003-11-10 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| CA2486362A1 (en) | 2002-06-06 | 2003-12-18 | Tze Chein Wun | Novel recombinant anticoagulant proteins |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20040213738A1 (en) | 2003-03-31 | 2004-10-28 | Susan Croll-Kalish | CIRL3-Like proteins, nucleic acids, and methods of modulating CIRL3-L-mediated activity |
| DE602004024195D1 (de) | 2003-05-19 | 2009-12-31 | Seikagaku Kogyo Co Ltd | Sulfatgruppen-transferase-hemmer |
| US7355018B2 (en) | 2003-09-30 | 2008-04-08 | Regeneron Pharmaceuticals, Inc. | Modified IGF1 polypeptides with increased stability and potency |
| US7736653B2 (en) * | 2003-11-13 | 2010-06-15 | Hanmi Pharm. Co., Ltd | Pharmaceutical composition comprising an immunoglobulin Fc region as a carrier |
| AU2005203962C1 (en) * | 2004-01-05 | 2012-11-08 | Antisoma Research Limited | Interleukin-12 targeted to oncofoetal fibronectin |
| EP1778270A4 (en) | 2004-05-05 | 2009-09-02 | Merrimack Pharmaceuticals Inc | BIS-SPECIFIC BINDER FOR MODULATING BIOLOGICAL ACTIVITY |
| US20060018897A1 (en) | 2004-06-28 | 2006-01-26 | Transtarget Inc. | Bispecific antibodies |
| US7511016B2 (en) * | 2004-07-07 | 2009-03-31 | Mosamedix B.V. | Annexins, derivatives thereof, and annexin-cys variants, as well as therapeutic and diagnostic uses thereof |
| US7531318B2 (en) | 2004-08-20 | 2009-05-12 | Board Of Regents, The University Of Texas System | Screening of agents for activity against ischemic myocardial insults |
| AU2005277094A1 (en) | 2004-08-20 | 2006-03-02 | Regenerx Biopharmaceuticals, Inc. | Method of treating, preventing, inhibiting or reducing damage to cardiac tissue |
| CA2582552A1 (en) | 2004-10-21 | 2006-05-04 | Igf Oncology, Llc | Toxins and radionuclides coupled to igf-1 receptor ligands for treatment of cancer |
| EP2289535B8 (en) * | 2004-12-21 | 2018-08-08 | MUSC Foundation for Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| AU2006203882B2 (en) | 2005-01-07 | 2011-05-12 | Regeneron Pharmaceuticals, Inc. | IGF-1 fusion polypeptides and therapeutic uses thereof |
| WO2006076525A2 (en) | 2005-01-14 | 2006-07-20 | Cytogen Corporation | Combination cancer therapy with anti-psma antibodies |
| NZ556065A (en) | 2005-01-24 | 2009-04-30 | Univ Texas | FC-fusion constructs binding to phosphatidylserine and their therapeutic use |
| BRPI0519897A2 (pt) | 2005-02-23 | 2009-08-18 | Merrimack Pharmaceuticals Inc | método para modular a atividade ou atividades biológicas de moléculas alvo em uma célula alvo, agente de ligação biespecìfico, composição, uso de um agente de ligação biespecìfico, e, kit |
| US7521211B2 (en) * | 2005-04-05 | 2009-04-21 | Regeneron Pharmaceuticals, Inc | IGF-1 and IGF-2 chimeric polypeptides and therapeutic uses thereof |
| CA2609728A1 (en) * | 2005-05-27 | 2006-11-30 | Five Prime Therapeutics, Inc. | Methods of and compositions for stimulation of glucose uptake into muscle cells and treatment of diseases |
| MX2008001865A (es) | 2005-08-12 | 2008-04-15 | Human Genome Sciences Inc | Proteinas de fusion de albumina. |
| US7855279B2 (en) | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| WO2007044887A2 (en) | 2005-10-11 | 2007-04-19 | Transtarget, Inc. | Method for producing a population of homogenous tetravalent bispecific antibodies |
| NZ569078A (en) | 2005-12-12 | 2012-01-12 | Mosamedix Bv | Annexin derivatives suitable for pretargeting in therapy and diagnosis |
| US7776816B2 (en) | 2006-01-20 | 2010-08-17 | Board Of Regents, The University Of Texas System | Preserving hypoxic tissue |
| KR20080098504A (ko) * | 2006-02-03 | 2008-11-10 | 메디뮨 엘엘씨 | 단백질 제제 |
| EA200870265A1 (ru) | 2006-02-15 | 2009-02-27 | Имклоун Системз Инкорпорейтед | Функционально активные антитела |
| JP5374359B2 (ja) * | 2006-03-17 | 2013-12-25 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | 安定化されたポリペプチド化合物 |
| US9187517B2 (en) | 2006-11-13 | 2015-11-17 | The Brigham And Women's Hospital, Inc. | Methods of promoting cardiac repair using growth factors fused to heparin binding sequences |
| US8003761B2 (en) * | 2007-01-23 | 2011-08-23 | Hoffmann-La Roche Inc. | Cancerous disease modifying antibodies |
| SE530073C2 (sv) | 2007-01-23 | 2008-02-26 | Teknikbolaget K Samuelsson Ab | Sprutmunstycksanordning för brandsläckningssystem |
| WO2008124086A2 (en) | 2007-04-05 | 2008-10-16 | President And Fellows Of Harvard College | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| US20110045007A1 (en) | 2007-05-31 | 2011-02-24 | Genmab A/S | Fusion or linked proteins with extended half life |
| WO2008151005A2 (en) | 2007-05-31 | 2008-12-11 | Transtarget, Inc. | Compositions and methods for tissue repair |
| KR101631323B1 (ko) | 2007-06-21 | 2016-06-17 | 엑스엘-프로테인 게엠베하 | 증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질 |
| WO2009030720A2 (en) | 2007-09-06 | 2009-03-12 | Novozymes Biopharma Dk A/S | Process for producing a recombinant protein |
| JP5639039B2 (ja) | 2008-04-11 | 2014-12-10 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| JP5677972B2 (ja) | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| CA2751068A1 (en) | 2009-01-31 | 2010-08-05 | Igf Oncology, Llc | Anti-cancer protein-platinum conjugates |
| WO2011011071A2 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Analogues of insulin-like growth factor-1 (igf-1) |
| MX2012000757A (es) | 2009-07-22 | 2012-08-03 | Ipsen Pharma Sas | Analogos de factor de crecimiento insulinoide tipo 1 (igf-1) que tienen sustitucion de aminoacidos en la posicion 59. |
| JP2013507926A (ja) | 2009-10-14 | 2013-03-07 | メリマック ファーマシューティカルズ インコーポレーティッド | ＩＧＦ−１Ｒ及びＥｒｂＢ３シグナル伝達を標的とする二重特異的結合剤及びその使用 |
| WO2011051489A2 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
| EP2571992B1 (en) * | 2010-05-21 | 2018-04-25 | Merrimack Pharmaceuticals, Inc. | Bi-specific fusion proteins |
| AU2010365057B2 (en) | 2010-12-08 | 2016-12-22 | Viacyte, Inc. | Agents and methods for inhibiting human pluripotent stem cell growth |
| HK1200842A1 (en) | 2011-11-18 | 2015-08-14 | Albumedix Ltd | Proteins with improved half-life and other properties |
| CN109180802A (zh) | 2011-12-15 | 2019-01-11 | 爱德迪安（北京）生物技术有限公司 | 具有降血糖作用的化合物、组合物及其用途 |
| EP3395358B1 (en) | 2012-09-26 | 2019-11-06 | Indiana University Research and Technology Corporation | Insulin analog dimers |
| KR20150134417A (ko) | 2013-03-29 | 2015-12-01 | 메리맥 파마슈티컬즈, 인크. | 연골-결합 융합 단백질 |
| US9675671B2 (en) | 2014-01-12 | 2017-06-13 | Igf Oncology, Llc | Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof |
| ES2863278T3 (es) * | 2015-10-02 | 2021-10-11 | Silver Creek Pharmaceuticals Inc | Proteínas terapéuticas biespecíficas para la reparación de tejidos |
| US11290711B2 (en) | 2018-10-06 | 2022-03-29 | Mediatek Inc. | Method and apparatus of shared merge candidate list region for video coding |
-
2011
- 2011-05-20 EP EP11729797.8A patent/EP2571992B1/en active Active
- 2011-05-20 US US13/112,907 patent/US8691771B2/en active Active
- 2011-05-20 CN CN201180035656.1A patent/CN103124788B/zh active Active
- 2011-05-20 WO PCT/US2011/037459 patent/WO2011146902A1/en not_active Ceased
- 2011-05-20 JP JP2013511403A patent/JP6200806B2/ja active Active
- 2011-05-20 CA CA2800173A patent/CA2800173C/en active Active
- 2011-05-20 AU AU2011255238A patent/AU2011255238B2/en active Active
- 2011-05-20 BR BR112012029611A patent/BR112012029611A2/pt not_active Application Discontinuation
- 2011-05-20 US US13/068,808 patent/US9238080B2/en active Active
- 2011-05-20 ES ES11729797T patent/ES2674567T3/es active Active
-
2014
- 2014-02-24 US US14/187,728 patent/US9982060B2/en active Active
-
2015
- 2015-12-14 US US14/967,980 patent/US9718892B2/en active Active
-
2016
- 2016-06-30 JP JP2016130526A patent/JP6174763B2/ja active Active
-
2017
- 2017-06-09 US US15/618,478 patent/US10407512B2/en active Active
- 2017-07-06 JP JP2017132859A patent/JP6822911B2/ja active Active
-
2018
- 2018-04-19 US US15/957,252 patent/US10858450B2/en active Active
-
2019
- 2019-06-25 JP JP2019117073A patent/JP6965311B2/ja active Active
- 2019-07-29 US US16/524,451 patent/US10988547B2/en active Active
-
2020
- 2020-10-23 US US17/078,978 patent/US11673970B2/en active Active
-
2021
- 2021-03-25 US US17/212,270 patent/US11814443B2/en active Active
-
2023
- 2023-05-03 US US18/311,306 patent/US20230322951A1/en active Pending
- 2023-10-09 US US18/483,308 patent/US20240101713A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019196365A5 (enExample) | ||
| JP2013530146A5 (enExample) | ||
| JP7685737B2 (ja) | 疾患の治療または予防に用いるためのファクター１およびファクター２タンパク質、およびその阻害剤 | |
| JP2018511327A5 (enExample) | ||
| JP2022105138A5 (enExample) | ||
| JP2017000143A5 (enExample) | ||
| JP2019535763A5 (enExample) | ||
| JP2020537644A5 (enExample) | ||
| JP2010505830A5 (enExample) | ||
| JP2005521383A5 (enExample) | ||
| CN111527109A (zh) | 以抗体Fc区为骨架的融合蛋白二聚体及其应用 | |
| JP2016510763A5 (enExample) | ||
| JP2020506701A (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| JP2010202664A5 (enExample) | ||
| JP2021502810A5 (enExample) | ||
| CN105524176B (zh) | 双特异性融合蛋白 | |
| JP2017536111A5 (enExample) | ||
| AR065289A1 (es) | Antagonistas de activina - actriia y sus usos para la promocion del crecimiento oseo y el tratamiento de mieloma multiple | |
| JP2019519215A5 (enExample) | ||
| CN103124788A (zh) | 双特异性融合蛋白 | |
| JP2019031567A5 (enExample) | ||
| JP2005507647A5 (enExample) | ||
| CN103687946A (zh) | 用于诱导组织再生的肽及其应用 | |
| JP2020521478A5 (enExample) | ||
| JP2015522576A5 (enExample) |